Chairman of Board; Founder & CEO
◇  Boston Univ. (Ph.D.), Harvard Univ. (postdoc)
◇  18 years @ Wyeth/Pfizer, JNJ (Head of Chemistry)
◇  >40 Journal publications; >140 global & regional patents.
◇  HSD-016, HSD-621 & PF-06700841 (Phase II) & Halaven^TM
◇  Co-founder, Chinese BioMedical Association (CABA)
◇  Fellow of the Royal Society of Chemistry, RSC, UK
◇  Young Industrial Investigators Award, American Chemical Society
◇  Steering Committee Member, CICR, AACR

Co-founder & CSO
◇  Kobe Unive. (Ph.D.); UT S.W. Medical Center (postdoc)
◇  >25 years @ Merck, Medicilon
◇  Publications in Nature, PNAS, JBC; >40 US global & regional patents.
◇  Invanz®, KU-2285, AK-2123, Platensimycin & Platencin
◇  Outstanding reviewer for Biochem. Pharmacol. 2015
◇  Leadership Award, Merck, 2003
◇  Distinguished Director, Cancer Institute of CAMS 1989
◇  Editorial Board Members for 3 English Journals

Co-founder, SVP & Head of Chemistry
◇  Northwestern Univ. (Ph.D.); RTI (Postdoc)
◇  >30 years @ Pharmacia/Pfizer (Director & Associate Research Fellow)
◇  >20 Journal publications; >470 global & regional patents.
◇  Agenerase^®, Lexiva^®, Prezista^® & Xalkori^®
    PF-04965842 (Phase III), PF-06763809 (Phase Ib)
◇  Distinguished Alumni (2016), Northern Illinois University;
◇ Frequently invited speakers at conferences & universities

CMO
◇ Louisiana State University ( Ph.D ), Pittsburgh Medical School
(Postdoc) Beijing Medical College( M.D )
◇ 26+ year experience in global clinical development strategy/
execution across multiple therapeutic areas in advancing multiple
drugs from clinical development to registration
◇ SVP of Clinical Development at Seres Therapeutics; Leadership positions in Shire/Baxalta, Takeda, Novo Nordisk overseeing clinical development programs across immunological/inflammatory diseases, immune-oncology, metabolic disease, vaccines, gene therapy for hemophilia, neurological disorders.